Amy Puenpatom

473 total citations
39 papers, 299 citations indexed

About

Amy Puenpatom is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Amy Puenpatom has authored 39 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hepatology, 17 papers in Epidemiology and 15 papers in Infectious Diseases. Recurrent topics in Amy Puenpatom's work include Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (9 papers) and Hepatitis B Virus Studies (8 papers). Amy Puenpatom is often cited by papers focused on Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (9 papers) and Hepatitis B Virus Studies (8 papers). Amy Puenpatom collaborates with scholars based in United States, United Kingdom and Japan. Amy Puenpatom's co-authors include Hashem B. El‐Serag, Jennifer R. Kramer, Israel C. Christie, Fasiha Kanwal, Diana Castillo, Elizabeth R. Duke, Fasiha Kanwal, Adeel A. Butt, Ritesh Kumar and Michael Hüll and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Amy Puenpatom

37 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Puenpatom United States 10 162 158 118 30 18 39 299
Inmaculada Jiménez-Nàcher Spain 9 265 1.6× 235 1.5× 246 2.1× 6 0.2× 19 1.1× 19 471
L. Pasulo Italy 10 209 1.3× 183 1.2× 87 0.7× 38 1.3× 7 0.4× 34 314
Pierluigi Blanc Italy 9 94 0.6× 119 0.8× 64 0.5× 22 0.7× 10 0.6× 18 246
Maria Aurora Carleo Italy 8 65 0.4× 78 0.5× 90 0.8× 14 0.5× 4 0.2× 15 232
Maryam Darvishian Canada 14 432 2.7× 434 2.7× 123 1.0× 17 0.6× 3 0.2× 34 562
Mohamed Eltabbakh Egypt 10 311 1.9× 301 1.9× 66 0.6× 19 0.6× 2 0.1× 23 443
Stefan Bourgeois Belgium 11 540 3.3× 535 3.4× 124 1.1× 6 0.2× 6 0.3× 49 708
Shahnaz Sali Iran 9 156 1.0× 195 1.2× 60 0.5× 22 0.7× 4 0.2× 44 287
Reham Soliman Egypt 15 533 3.3× 517 3.3× 71 0.6× 8 0.3× 10 0.6× 49 651
К. В. Жданов Russia 9 133 0.8× 191 1.2× 93 0.8× 18 0.6× 85 273

Countries citing papers authored by Amy Puenpatom

Since Specialization
Citations

This map shows the geographic impact of Amy Puenpatom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Puenpatom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Puenpatom more than expected).

Fields of papers citing papers by Amy Puenpatom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Puenpatom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Puenpatom. The network helps show where Amy Puenpatom may publish in the future.

Co-authorship network of co-authors of Amy Puenpatom

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Puenpatom. A scholar is included among the top collaborators of Amy Puenpatom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Puenpatom. Amy Puenpatom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Puenpatom, Amy, et al.. (2024). Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review. Infectious Diseases and Therapy. 13(6). 1177–1198. 4 indexed citations
2.
Puenpatom, Amy, Matthew G. Johnson, Ying Zhang, et al.. (2023). Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial. Clinical Infectious Diseases. 77(11). 1521–1530. 9 indexed citations
3.
Maan, Raoel, Amy Puenpatom, Nicole S. Erler, et al.. (2023). Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease. BMJ Open Gastroenterology. 10(1). e001209–e001209. 1 indexed citations
4.
5.
Dalgård, Olav, Alain H. Litwin, Oren Shibolet, et al.. (2022). Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal of Addictive Diseases. 41(3). 213–224. 3 indexed citations
6.
7.
Jiang, Yiling, et al.. (2022). Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. PharmacoEconomics. 40(7). 699–714. 22 indexed citations
8.
Kramer, Jennifer R., Amy Puenpatom, Yumei Cao, et al.. (2022). Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. The American Journal of Drug and Alcohol Abuse. 48(4). 445–453. 1 indexed citations
9.
Gruttola, Victor De, Frank de Vocht, Sharon Hutchinson, et al.. (2021). Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. PubMed. 13(1). 20200005–20200005. 2 indexed citations
10.
Dalén, Johan, Amy Puenpatom, Karin Luttropp, Axel Svedbom, & Christopher M. Black. (2021). Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study. Advances in Therapy. 39(1). 244–255. 4 indexed citations
11.
Luttropp, Karin, Johan Dalén, Axel Svedbom, et al.. (2020). <p>Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review</p>. Patient Preference and Adherence. Volume 14. 309–320. 14 indexed citations
12.
Puenpatom, Amy, Yumei Cao, Xian Yu, et al.. (2020). Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection. Infectious Diseases and Therapy. 9(2). 355–365. 3 indexed citations
13.
Puenpatom, Amy, et al.. (2020). Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterology. 7(1). e000476–e000476. 8 indexed citations
14.
Kramer, Jennifer R., Amy Puenpatom, Yumei Cao, Hashem B. El‐Serag, & Fasiha Kanwal. (2019). THU-171-Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection receiving dialysis. Journal of Hepatology. 70(1). e237–e237.
15.
Dozier, Mary, Karin Luttropp, Axel Svedbom, et al.. (2019). AB0402 MEASURING PATIENT EXPERIENCE OF SWITCHING BIOLOGIC TREATMENT – A SYSTEMATIC LITERATURE REVIEW. Annals of the Rheumatic Diseases. 78. 1661–1661. 2 indexed citations
16.
Puenpatom, Amy, Xian Yu, Kevin F. Erickson, et al.. (2019). Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Research. 174. 104698–104698. 9 indexed citations
17.
18.
Butt, Adeel A., Yupeng Ren, Amy Puenpatom, et al.. (2018). Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Alimentary Pharmacology & Therapeutics. 48(1). 35–43. 25 indexed citations
19.
Puenpatom, Amy, et al.. (2017). Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infectious Diseases and Therapy. 6(3). 423–433. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Inmaculada Jiménez-Nàcher Breakdown of academic impact, for papers by L. Pasulo Breakdown of academic impact, for papers by Pierluigi Blanc Breakdown of academic impact, for papers by Maria Aurora Carleo Breakdown of academic impact, for papers by Maryam Darvishian Breakdown of academic impact, for papers by Mohamed Eltabbakh Breakdown of academic impact, for papers by Stefan Bourgeois Breakdown of academic impact, for papers by Shahnaz Sali Breakdown of academic impact, for papers by Reham Soliman Breakdown of academic impact, for papers by К. В. Жданов
Rankless by CCL
2026